Numerous studies in recent years have identified disturbance of gut microbial metabolism as a potential cause of chronic disease, leading researchers to begin studying the specific impact of the gut microbiome on cancers, including and . Another in Communications Biology found that gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation.
Inspired by this research, along with her own passion for metabolic and lifestyle medicine, AdventHealth Cancer Institute gynecologic oncologist , recently launched to begin exploring the interplay of the gut microbiome on the efficacy of immunotherapy treatment for gynecological cancers.
“This initial study is observational,” explains McKenzie, noting that the collection of microorganisms in the gut – including bacteria, archaea, viruses, and fungi – and their overall genetic information play an essential role in the health of its host, both in humans as well as animals.
The study is currently enrolling up to 30 participants with advanced or recurrent gynecological cancer who plan to receive immunotherapy treatment with a checkpoint inhibitor at AdventHealth.
“The gut microbiome’s key functions are all related to metabolism, immune system education and regulation, and protection against pathogen invasion,” McKenzie added. “This study will help us understand not only how the gut microbiome changes within the individual as they undergo immunotherapy, but also how it differs among patients throughout the course of their treatment.”
McKenzie, who is the principal investigator on this AdventHealth study, and her team will collect fecal, blood, saliva and vaginal samples three times: 1) prior to first treatment, 2) after four doses of immunotherapy, and 3) at the completion of immunotherapy.
These four biomarker samples will undergo metatranscriptomic analysis. Also known as RNA-seq, this method of sample analysis will only sequence RNA molecules while DNA is degraded to allow for bacterial community analysis. In addition, study participants will complete a prior to their first treatments.
The findings of this pilot feasibility study will help design a larger study to further examine the role of the gut microbiome in anti-tumor immunity and its effect on immune checkpoint inhibitor therapy for advanced or recurrent gynecological cancers.
“This study is just the first step,” shares McKenzie. “It will help us better understand the specific metabolites and bacteria that could impact treatment.”
This study is part of a collaboration with Viome Life Sciences, a systems biology and artificial intelligence company working to develop next generation of diagnostics and therapeutics to detect disease earlier and improve treatment.
AdventHealth collects the data and Viome analyzes the clinical specimens.
“From the specimens, we can generate vast amounts of molecular data relevant to chronic diseases and cancers,” said Momo Vuyisich, PhD, Viome Life Sciences chief science officer. “Machine learning and artificial intelligence then makes sense of the data and translates the findings into clinically useful diagnostics and therapeutics.”
Ultimately, McKenzie hopes to conduct additional studies to determine if specific interventions can be applied to influence the gut microbiome and create a better response to immunotherapy for gynecologic cancer patients.
“Using the principles of precision medicine, I want to explore if we can enhance efficacy and outcomes for our patients through lifestyle changes, nutraceuticals, oncology-specific microbial therapeutics or some combination of these approaches,” said McKenzie. “This is an exciting area of research, and I think we have multiple opportunities to improve and optimize cancer care — through prevention, pre-therapy preparation, therapy support and post-therapy protocols — to help women recover better, faster and with greater quality of life.”
Physicians with questions about this study or a specific gynecologic oncology case can contact AdventHealth GYN Oncology Nurse Navigator Althea Buckner, MSN, APRN-AOCNP, at Call407-303-5909.